ADAPY · Adaptimmune Therapeutics PLC
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| $65.09M | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M | $1.12M | $59.51M | $37.83M | $14.2M | |
| — | $70K | — | — | — | — | — | — | — | — | |
| — | $177.96M | — | — | — | — | — | — | — | — | |
| — | 99.96% | — | — | — | — | — | — | — | — | |
| $125.24M | $149.06M | $126.51M | $127.73M | $111.09M | $91.57M | $97.5M | $98.27M | $87.39M | $63.79M | |
| $71.86M | — | $73.51M | $63.39M | $57.31M | $45.8M | $43.39M | $43.6M | $31.11M | $23.21M | |
| $90.21M | $87.26M | $73.51M | $63.39M | — | — | — | — | — | — | |
| — | $411K | $387K | $809K | $937K | $967K | $838K | $622K | $391K | $160K | |
| — | $1.54M | $1.62M | $2.29M | — | — | — | — | — | — | |
| $229.31M | $246.79M | $200.02M | $191.11M | $168.4M | $137.36M | $140.89M | $141.87M | $118.49M | $87M | |
| -$164.22M | -$68.76M | -$139.74M | -$163.97M | -$162.25M | -$133.41M | -$139.77M | -$82.37M | -$80.66M | -$72.8M | |
| — | -38.62% | -231.82% | -603.97% | -2638.58% | -3370.52% | -12457.22% | -138.42% | -213.2% | -512.74% | |
| — | $3.35M | — | — | — | — | — | — | — | — | |
| $4.47M | — | — | — | — | — | $2.77M | $2.85M | $2.23M | $1.11M | |
| -$1.18M | -$1.73M | -$807K | -$536K | $3.85M | $1.16M | $75K | -$15.5M | $8.74M | $1M | |
| -$166.05M | -$67.24M | -$112.54M | -$162.96M | -$157.3M | -$129.93M | -$136.92M | -$95.02M | -$69.69M | -$70.69M | |
| $3.71M | $3.58M | $1.34M | $2.5M | $791K | $162K | $242K | $497K | $451K | $892K | |
| -$169.76M | -$70.81M | -$113.87M | -$165.46M | -$158.09M | -$130.09M | -$137.17M | -$95.51M | -$70.14M | -$71.58M | |
| — | -39.78% | -188.9% | -609.46% | -2570.99% | -3286.81% | -12225.04% | -160.51% | -185.39% | -504.15% | |
| -$176.96M | -$68.97M | -$116.74M | -$155.19M | -$159.18M | -$132.88M | -$134.67M | -$83.64M | -$77.53M | -$77.69M | |
| USD/shares | -$0.12 | -$0.05 | -$0.09 | -$0.17 | -$0.17 | -$0.15 | -$0.22 | — | — | — |
| USD/shares | -$0.11 | -$0.05 | -$0.09 | -$0.17 | -$0.17 | -$0.15 | -$0.22 | — | — | — |
| shares | — | 1.51B | 1.21B | 967.24M | 934.83M | 854.78M | 629.81M | 584.34M | 527.64M | 424.71M |
| shares | — | 1.51B | 1.21B | 967.24M | 934.83M | 854.78M | 629.81M | 584.34M | 527.64M | 424.71M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 275 similar-size Biotechnology companies (of 524 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Single Reportable Segment | $178,032,000 | $60,281,000 | $27,148,000 |
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Development Revenue | $176,796,000 | $60,281,000 | $27,148,000 | $6,149,000 | $3,958,000 | $1,122,000 | — |
| Product | $1,236,000 | — | — | — | — | — | — |
| Development and Service | — | — | — | — | — | — | $20,391,000 |
| License Revenue | — | — | — | — | — | — | $39,114,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Single Reportable Segment | -$68,760,000 | -$139,741,000 | -$163,965,000 |
Operating Margin by Segment (%)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Single Reportable Segment | -38.6% | -231.8% | -604% |